ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Isabel C Arrillaga-RomanySharon L GardnerYazmin OdiaDolly AguileraJoshua E AllenTracy T BatchelorNicholas A ButowskiClark C ChenTimothy F CloughesyAndrew ClusterJohn de GrootKaran S DixitJerome J GraberAya M HaggiagiRebecca A HarrisonAlbert KheradpourLindsay B KilburnSylvia C KurzGuangrong LuTobey J MacDonaldMinesh P MehtaAllen S MelemedPhioanh Leia NghiemphuSamuel C RamageNicole A ShonkaAshley L SumrallRohinton S TaraporeLynne P TaylorYoshie UmemuraPatrick Yung WenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
ONC201 monotherapy was well tolerated and exhibited durable and clinically meaningful efficacy in recurrent H3 K27M-mutant DMG.